ThromboGenics will exclusively license its technology to Millipore for the company to produce its stem cell culture medium, RESGRO™.
Under this global license agreement agreement, ThromboGenics will license to Millipore its patents, data, and know-how for the manufacturing, development, and evaluation of RESGRO. Millipore will assume responsibility for the exclusive production and sales of the medium as well as all future costs. ThromboGenics will receive upfront and milestone payments and will earn double digit royalties on Millipore's sales.
The technology for producing RESGRO was originally developed by the ThromboGenics drug discovery team as part of its efforts to identify several of its drug discovery candidates currently in clinical trials.